More about
Epidermal Growth Factor
Clinical Guidance
Non-Small Cell Lung Cancer
Treatment Options
Precision and Immune-Based Therapies
News
September 19, 2024
1 min read
Save
FDA grants fast track designation to ATR-04 for cancer therapy-induced skin rash
The FDA has granted fast track designation to topically applied ATR-04 for the treatment of moderate to severe epidermal growth factor receptor inhibitor-associated dermal toxicity, Azitra announced in a press release.
News
August 26, 2024
1 min read
Save
FDA clears development of drug to treat cancer therapy-induced skin rash
The FDA has cleared an investigational new drug application for a first-in-human phase 1/2 study of ATR-04 for moderate to severe dermal toxicity from epidermal growth factor receptor inhibitors, Azitra Inc. announced in a press release.
News
June 17, 2022
2 min watch
Save
VIDEO: First-line anti-EGF vs. anti-VEGF in certain patients with colorectal cancer
In this video, Howard S. Hochster, MD, FACP, discusses a late-breaking abstract on the phase 3 PARADIGM trial, which looked at panitumumab vs. bevacizumab as first-line treatment in patients with RAS wild-type metastatic colorectal cancer.